JP2009519298A - 新規なポリ不飽和化合物、これらの化合物の製造方法、およびこれらの化合物を含む組成物 - Google Patents
新規なポリ不飽和化合物、これらの化合物の製造方法、およびこれらの化合物を含む組成物 Download PDFInfo
- Publication number
- JP2009519298A JP2009519298A JP2008545006A JP2008545006A JP2009519298A JP 2009519298 A JP2009519298 A JP 2009519298A JP 2008545006 A JP2008545006 A JP 2008545006A JP 2008545006 A JP2008545006 A JP 2008545006A JP 2009519298 A JP2009519298 A JP 2009519298A
- Authority
- JP
- Japan
- Prior art keywords
- group
- dimethyl
- formula
- trimethyl
- cyclohex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000008569 process Effects 0.000 title claims description 13
- -1 hydroxy, acetoxy Chemical group 0.000 claims abstract description 22
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 9
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 7
- 230000002087 whitening effect Effects 0.000 claims abstract description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 6
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 5
- 125000005649 substituted arylene group Chemical group 0.000 claims abstract description 5
- 125000004450 alkenylene group Chemical group 0.000 claims abstract description 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 3
- 125000004419 alkynylene group Chemical group 0.000 claims abstract description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 3
- 125000005313 fatty acid group Chemical group 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 6
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- WLJVNTCWHIRURA-UHFFFAOYSA-N Heptanedioic acid Natural products OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 5
- 229960002255 azelaic acid Drugs 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000006722 reduction reaction Methods 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- JIXVIHXUBBLRJH-MHNRNSARSA-N (2e,4e,6e,8e)-3,7-dimethyl-9-[2,6,6-trimethyl-3-[4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenoxy]cyclohexen-1-yl]nona-2,4,6,8-tetraenoic acid Chemical compound C1CC(C)(C)C(/C=C/C(/C)=C/C=C/C(/C)=C/C(O)=O)=C(C)C1OC(C=C1)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JIXVIHXUBBLRJH-MHNRNSARSA-N 0.000 claims description 4
- LWSSPFQKNRHGPK-UHFFFAOYSA-N 8-hydroxy-5-methyloct-2-enoic acid Chemical compound OCCCC(C)CC=CC(O)=O LWSSPFQKNRHGPK-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 229940049918 linoleate Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000001384 succinic acid Substances 0.000 claims description 4
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 claims description 4
- QNRPTYCCJFVAGS-MZXQKSLLSA-N (2e,4e,6e,8e)-9-[3-(4-methoxyphenoxy)-2,6,6-trimethylcyclohexen-1-yl]-3,7-dimethylnona-2,4,6,8-tetraenal Chemical compound C1=CC(OC)=CC=C1OC1C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C=O)C(C)(C)CC1 QNRPTYCCJFVAGS-MZXQKSLLSA-N 0.000 claims description 3
- XLHUBROMZOAQMV-UHFFFAOYSA-N 1,4-benzosemiquinone Chemical group [O]C1=CC=C(O)C=C1 XLHUBROMZOAQMV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
- LAMNFFJJKSFCML-FYWRMAATSA-N CC=1C(CCC(C1)(C)C)OC(\C=C\CCCCCCCCCCCO)=O Chemical compound CC=1C(CCC(C1)(C)C)OC(\C=C\CCCCCCCCCCCO)=O LAMNFFJJKSFCML-FYWRMAATSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- YYUCCLBSNGESIQ-ZWYDQDKLSA-N (2e,4e,6e,8e)-9-[3-(4-hydroxyphenoxy)-2,6,6-trimethylcyclohexen-1-yl]-3,7-dimethylnona-2,4,6,8-tetraenal Chemical compound C1CC(C)(C)C(/C=C/C(/C)=C/C=C/C(/C)=C/C=O)=C(C)C1OC1=CC=C(O)C=C1 YYUCCLBSNGESIQ-ZWYDQDKLSA-N 0.000 claims description 2
- 239000001195 (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid Substances 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- KPECRSANFCYQDK-PKNBQFBNSA-N CC=1C(CCC(C1)(C)C)OC(\C=C\CCCCCCCO)=O Chemical compound CC=1C(CCC(C1)(C)C)OC(\C=C\CCCCCCCO)=O KPECRSANFCYQDK-PKNBQFBNSA-N 0.000 claims description 2
- 206010040825 Skin depigmentation Diseases 0.000 claims description 2
- AUXPKBDZZOGTOQ-DGCFGCRSSA-N [3-[(1e,3e,5e,7e)-3,7-dimethyl-9-oxonona-1,3,5,7-tetraenyl]-2,4,4-trimethylcyclohex-2-en-1-yl] (e)-10-acetyloxydec-2-enoate Chemical compound CC(=O)OCCCCCCC\C=C\C(=O)OC1CCC(C)(C)C(\C=C\C(\C)=C\C=C\C(\C)=C\C=O)=C1C AUXPKBDZZOGTOQ-DGCFGCRSSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 230000035614 depigmentation Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229940040452 linolenate Drugs 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000007854 depigmenting agent Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 82
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 239000000377 silicon dioxide Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000004949 mass spectrometry Methods 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 239000012429 reaction media Substances 0.000 description 13
- 239000012043 crude product Substances 0.000 description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 239000011734 sodium Substances 0.000 description 9
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229960000271 arbutin Drugs 0.000 description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 5
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IFABLCIRROMTAN-MDZDMXLPSA-N (e)-1-chlorooctadec-9-ene Chemical class CCCCCCCC\C=C\CCCCCCCCCl IFABLCIRROMTAN-MDZDMXLPSA-N 0.000 description 4
- 0 CCCC1(C)O*2=*C(CC)C=C(OC(*CC=C*)=O)S*2CC1 Chemical compound CCCC1(C)O*2=*C(CC)C=C(OC(*CC=C*)=O)S*2CC1 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 150000004665 fatty acids Chemical group 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 2
- DZXHSXTZBFGKCI-IMOFWGLTSA-N 3-[(1e,3e,5e,7e)-3,7-dimethylnona-1,3,5,7-tetraenyl]-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C DZXHSXTZBFGKCI-IMOFWGLTSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- YWVBBOAWJPAPPF-IMOFWGLTSA-N C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C Chemical compound C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C YWVBBOAWJPAPPF-IMOFWGLTSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- RKEBSYCVOHHSDE-QZGFXHMPSA-N tert-butyl (2e,4e,6e,8e)-9-[3-(4-methoxyphenoxy)-2,6,6-trimethylcyclohexen-1-yl]-3,7-dimethylnona-2,4,6,8-tetraenoate Chemical compound C1=CC(OC)=CC=C1OC1C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(=O)OC(C)(C)C)C(C)(C)CC1 RKEBSYCVOHHSDE-QZGFXHMPSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- BVHMITOWPMCRLY-HZJYTTRNSA-N (6z,9z)-18-chlorooctadeca-6,9-diene Chemical group CCCCC\C=C/C\C=C/CCCCCCCCCl BVHMITOWPMCRLY-HZJYTTRNSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DOPFRSWQQFJVHQ-NSCUHMNNSA-N (e)-tetradec-12-enoic acid Chemical compound C\C=C\CCCCCCCCCCC(O)=O DOPFRSWQQFJVHQ-NSCUHMNNSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZLTWIJREHQCJJL-UHFFFAOYSA-N 1-trimethylsilylethanol Chemical compound CC(O)[Si](C)(C)C ZLTWIJREHQCJJL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZEMZMIXJGXDWTG-COIZJCGZSA-N 2-trimethylsilylethyl (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate Chemical compound C[Si](C)(C)CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C ZEMZMIXJGXDWTG-COIZJCGZSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- CSBMGHZVZXFFBD-UTJQPWESSA-N CC=1C(CCC(C1)(C)C)OC(CCCCCCC\C=C/C\C=C/CCCCC)=O Chemical compound CC=1C(CCC(C1)(C)C)OC(CCCCCCC\C=C/C\C=C/CCCCC)=O CSBMGHZVZXFFBD-UTJQPWESSA-N 0.000 description 1
- QJINGMWYMMHVCS-YVDNJGTBSA-N CCCCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C Chemical compound CCCCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QJINGMWYMMHVCS-YVDNJGTBSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- CYAYKKUWALRRPA-RGDJUOJXSA-N [(2r,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@H](Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O CYAYKKUWALRRPA-RGDJUOJXSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical group CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N retinal Chemical compound O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229910001925 ruthenium oxide Inorganic materials 0.000 description 1
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FESDUDPSRMWIDL-UHFFFAOYSA-N tert-butyl n,n'-di(propan-2-yl)carbamimidate Chemical compound CC(C)NC(OC(C)(C)C)=NC(C)C FESDUDPSRMWIDL-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
- C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Saccharide Compounds (AREA)
Abstract
(上記式中、
R1は、R'1、-A-R'1基であり、
R'1は、-COOH、-COOR3、-CONH2、-CONHR3、-CONR3R4、-CHO、-CH2OH、-CH2OR5から選択され、
Aは、C2-C16アルキレン、アルケニレン、またはアルキニレンであり、
R2は、場合によって置換されたアリール基または場合によって置換されたヘテロアリール基、オシド残基、または場合によって分岐しおよび/または好ましくは末端が特にヒドロキシ、アセトキシ基によってまたは保護されているもしくは保護されていないアミノ基によって置換された脂肪酸残基、-OC-(CH2)nCO-トコフェリル(α、β、γ、またはδ)基(但し、2 ≦ n ≦ 10)、-R'2-O-R6基 (式中、R'2は場合によって置換されたアリーレン基または場合によって置換されたヘテロアリーレン基であり、R6は水素原子、直鎖状もしくは分岐状の場合によって置換されたC1-C16アルキル、直鎖状もしくは分岐状の場合によって置換されたC2-C16アルケニル、または直鎖状もしくは分岐状のC2-C16アルキニル基、場合によって置換されたトコフェリル基などである)、アミノ酸残基、またはオシド残基である)。本発明は、特に少なくとも1種類の式(I)の化合物を含む化粧用および/または皮膚用組成物、並びに白色化および/または脱色剤としてのそれらの使用、上記組成物を用いる化粧方法にも関する。
Description
本発明は、レチノイドの新規なポリ不飽和誘導体、それらの製造方法、それらを含む組成物、および化粧品および/または皮膚科学の分野におけるそれらの使用に関する。
現在、レチノイン酸誘導体は、乾癬または魚鱗癬などの様々な適応症および皮膚の脱色素(ビタミンAの作用下でのメラニン産生の減少)における皮膚科学の分野において用いられている。
R1はR'1または-A-R'1基であり、R'1は-COOH、-COOR3、-CONH2、-CONHR3、-CONR3R4、-CHO、-CH2OH、-CH2OR5から選択され、Aは直鎖状もしくは分岐状のC1-C16アルキレン基、直鎖状もしくは分岐状のC2-C16アルケニレン基、または直鎖状もしくは分岐状のC2-C16アルキニレン基であり、
R2は:
・場合によって置換されたアリール基もしくは場合によって置換されたヘテロアリール基、または
・オシド残基、または
・場合によって分岐しおよび/または好ましくは鎖の末端が、特にヒドロキシ、アセトキシまたは保護されたもしくは保護されていないアミノ残基によって置換された脂肪酸残基、
・-OC-(CH2)nCO-(α、β、γ、またはδ)トコフェリル基(但し、2≦n≦10)、
・-R'2-O-R6基
(上記式中、R'2は場合によって置換されたアリーレン基または場合によって置換されたヘテロアリーレン基であり、R6は水素原子、直鎖状もしくは分岐状の場合によって置換されたC1-C16アルキル基、直鎖状もしくは分岐状の場合によって置換されたC2-C16アルケニル基、または直鎖状もしくは分岐状の場合によって置換されたC2-C16アルキニル基、直鎖状もしくは分岐状の場合によって置換されたトコフェリル基もしくは類似体、アミノ酸残基、またはオシド残基である)を表し、
R3およびR4は、独立して、直鎖状もしくは分岐状の場合によって置換されたC1-C16アルキル基、直鎖状もしくは分岐状のC2-C16アルケニル、または直鎖状もしくは分岐状の場合によって置換されたC2-C16アルキニルであり、
R5は、直鎖状もしくは分岐状の場合によって置換されたC1-C16アルキル基、直鎖状もしくは分岐状の場合によって置換されたC2-C16アルケニル基、直鎖状もしくは分岐状の場合によって置換されたC2-C16アルキニル基、または直鎖状もしくは分岐状の場合によって置換されたC2-C16アシル基である)。
(2E,4E,6E,8E)-3,7-ジメチル-9-{2,6,6-トリメチル-3-[4-((2S,3R,4S,5S,6R)-3,4,5-トリヒドロキシ-6-ヒドロキシメチル-テトラヒドロ-ピラン-2-イルオキシ)-フェノキシ]-シクロへキス-1-エニル}-ノナ-2,4,6,8-テトラエン酸
の3位においてアリル酸化反応を行い、式(III)の化合物:
を得て、
次に、その3位のカルボニル基を還元して対応する式(IV)のアルコール:
化合物(IV)をアルカリ性、酸性、または中性媒質中において、場合によりカップリング試薬の存在下において、式R2-X (上記式中、Xはヒドロキシ基またはハロゲン原子であるが、ヒドロキシ基は必要ならば出発基の形態により当然活性化させることができる)の試薬を用いてアルキル化反応またはカップリング反応を行って、式(I)の化合物の具体例である式(Ia)の化合物:
を生成させ、
これを、基R10が基-COOR3である場合には、加水分解または還元反応を行って、式(I)の化合物の具体例である式(Ib)の化合物:
を生成させることができ、
上記化合物に含まれる様々な基は、当然、用いられる試薬の不適合性に依存し、保護後、任意の時間に脱保護した基の合成に適切であることを特徴とする式(I)の化合物の製造方法にも関する。本発明の範囲内で用いることができる保護基は、Protective Group in Organic Synthesis)」, Wiley-Interscience,3rd Edition,1999に記載されているような一般に用いられる基から選択される。
であって、上記されておりかつ本発明の範囲内において、式(I)の多数の化合物を得るための合成中間体として用いられる化合物にも関する。
(2E,4E,6E,8E)-3,7-ジメチル-9-(2,6,6-トリメチル-3-オキソ-シクロヘキス-1-エニル)-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル
工程1:過アセチル化アルブチン
Rf = 0.4 (トルエン/酢酸エチル 1/1)。
Rf = 0.6 (トルエン/酢酸エチル 1/1)。
(2E,4E,6E,8E)-3,7-ジメチル-9-{2,6,6-トリメチル-3-[4-((2S,3R,4S,5R,6R)-3,4,5-トリアセトキシ-6-アセトキシメチルテトラヒドロ-ピラン-2-イルオキシ)-フェノキシ]-シクロヘキス-1-エニル}-ノナ-2,4,6,8-テトラエン酸の2-トリメチルシラニル-エチルエステル
工程1:
(2E,4E,6E,8E)-3,7-ジメチル-9-(2,6,6-トリメチル-シクロヘキス-1-エニル)-ノナ-2,4,6,8-テトラエン酸の2-トリメチルシラニル-エチルエステル
Rf = 0.8 (ヘプタン/酢酸エチル 8/2)。
(2E,4E,6E,8E)-3,7-ジメチル-9-(2,6,6-トリメチル-3-オキソ-シクロヘキス-1-エニル)-ノナ-2,4,6,8-テトラエン酸の2-トリメチルシラニル-エチルエステル
Rf = 0.5 (ヘプタン/酢酸エチル 7/3)。
(2E,4E,6E,8E)-9-(3-ヒドロキシ-2,6,6-トリメチル-シクロヘキス-1-エニル)-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の2-トリメチルシラニル-エチルエステル
Rf = 0.4 (ヘプタン/酢酸エチル 7/3)
(2E,4E,6E,8E)-3,7-ジメチル-9-{2,6,6-トリメチル-3-[4-((2S,3R,4S,5R,6R)-3,4,5-トリアセトキシ-6-アセトキシメチル-テトラヒドロ-ピラン-2-イルオキシ)-フェノキシ]-シクロヘキス-1-エニル}-ノナ-2,4,6,8-テトラエン酸の2-トリメチルシラニル-エチルエステル
Rf = 0.3 (ヘプタン/酢酸エチル 7/3)
質量分析: [MNa+] 861 (計算値[MH+] 839)
(2E,4E,6E,8E)-3,7-ジメチル-9-{2,6,6-トリメチル-3-[4-((2S,3R,4S,5S,6R)-3,4,5-トリヒドロキシ-6-ヒドロキシメチル-テトラヒドロ-ピラン-2-イルオキシ)-フェノキシ]-シクロヘキス-1-エニル}-ノナ-2,4,6,8-テトラエン酸の2-トリメチルシラニル-エチルエステル
Rf = 0.1 (ヘプタン/酢酸エチル 7/3)
質量分析: [MNa+] 693 (計算値[MH+] 671)
(2E,4E,6E,8E)-3,7-ジメチル-9-{2,6,6-トリメチル-3-[4-((2S,3R,4S,5S,6R)-3,4,5-トリヒドロキシ-6-ヒドロキシメチル-テトラヒドロ-ピラン-2-イルオキシ)-フェノキシ]-シクロヘキス-1-エニル}-ノナ-2,4,6,8-テトラエン酸
Rf = 0.1ジクロロメタン/メタノール 9/1)
質量分析: [MNa+] 593 (計算値[MH+] 571)
(2E,4E,6E,8E)-9-[3-(4-メトキシ-フェノキシ)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル
工程1:
(2E,4E,6E,8E)-3,7-ジメチル-9-(2,6,6-トリメチル-シクロヘキス-1-エニル)-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル
Rf = 0.4 (ヘプタン/酢酸エチル 8/2)
(2E,4E,6E,8E)-3,7-ジメチル-9-(2,6,6-トリメチル-3-オキソ-シクロヘキス-1-エニル)-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル
Rf = 0.5 (ヘプタン/酢酸エチル 7/3)
(2E,4E,6E,8E)-9-(3-ヒドロキシ-2,6,6-トリメチル-シクロヘキス-1-エニル)-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル
Rf = 0.3 (ヘプタン/酢酸エチル 7/3)
(2E,4E,6E,8E)-9-[3-(4-メトキシ-フェノキシ)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル
Rf = 0.7 (ヘプタン/酢酸エチル 8/2)
質量分析: [MNa+] 501 (計算値[MH+]479)
(2E,4E,6E,8E)-9-[3-(4-メトキシ-フェノキシ)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7- ジメチル-ノナ-2,4,6,8-テトラエナール
Rf = 0.2 (ヘプタン/酢酸エチル 8/2)
質量分析: [MNa+] 429 ( 計算値[MH+]407)
(2E,4E,6E,8E)-9-[3-(4-ヒドロキシ-フェノキシ)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル
Rf = 0.6 (ヘプタン/酢酸エチル 7/3)
質量分析: [MNa+] 487 (計算値[MH+]465)
(2E,4E,6E,8E)-9-[3-(4-ヒドロキシ-フェノキシ)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7- ジメチル-ノナ-2,4,6,8-テトラエナール
上記化合物1.32g (2.28ミリモル)を、トルエン10容に窒素気流下にて遮光下において溶解した。媒質を-80℃に冷却し、20% Dibal-Hのトルエン溶2.46mlを徐々に加えた。媒質を20分間攪拌した後、ローゼン塩の飽和溶液20容を-78℃において加えた。激しく攪拌した後、媒質をトルエンにより抽出した。有機相を飽和NaCl溶液により洗浄し、MgSO4上において乾燥し、真空濃縮した。粗製混合物をシリカカラム上で精製し、ヘプタン/イソプロピルエーテルグラディエントで溶出した。黄色固形物0.58g (1.18ミリモル)を得た(収率51%)。
9-[(3-トランスデセノエート)-2,6,6トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル- ノナ-2,4,6,8テトラエナール
工程1:
9-(2,6,6-トリメチル-シクロヘキス-1-エニル)-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール
Rf = 0.2 (ヘプタン/酢酸エチル 7/3)
質量分析: [M+Na+] = 323 (計算値[MH+]300)
9-[(3-トランスデセノエート)-2,6,6トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ- 2,4,6,8テトラエナール
Rf = 0.7 (ヘプタン/酢酸エチル 7/3)
質量分析: [MNa+] 475 (計算値[MH+]452)
9-[(3-リノレエート)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8テトラエナール
Rf = 0.7 (ヘプタン/酢酸エチル 7/3)
質量分析: [MNa+] 587 (計算値[MH+]564)
9-[(3-リノレエート)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール
9-[(3-リポエート)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール
9-[{3-(8-ヒドロキシ-5-メチル-2-オクテノエート)}-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7- ジメチル-ノナ-2,4,6,8-テトラエナール
9-[(3-テトラアセチルグルコース)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール
Rf = 0.7 (ヘプタン/酢酸エチル 7/3)
質量分析: [M+Na+] = 653 (計算値[M+H]+ 630)
(9Z,12Z,15Z)-オクタデカ-9,12,15-トリエン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル
TLC (ヘプタン/酢酸エチル 7/3): Rf = 0.8
質量分析: [M+Na]+ = 583 (計算値 560)
(9Z,12Z)-オクタデカ-9,12-ジエン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル
(E)-14-ヒドロキシ-テトラデク-2-エン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル
TLC (ヘプタン/酢酸エチル 7/3): Rf = 0.2
質量分析: [M+Na]+ = 547 (計算値 524)
(E)-10-アセトキシ-デク-2-エン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル
TLC (ヘプタン/酢酸エチル 7/3): Rf = 0.4
(E)-10-ヒドロキシ-デク-2-エン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル
TLC (ヘプタン/酢酸エチル 7/3): Rf = 0.2
質量分析: [M+Na]+ = 491 (計算値 468)
ヘプタン二酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチル-トリデシル)-1-ベンゾピラン-6-イルビスエステル
TLC (ヘプタン/酢酸エチル 7/3): Rf = 0.5
質量分析: [M+Na]+ = 849 (計算値 827)
ノナン二酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチル-トリデシル)-1-ベンゾピラン-6-イルビスエステル
TLC (ヘプタン/酢酸エチル 7/3): Rf = 0.6
質量分析: [M+Na]+ = 877 (計算値 854)
コハク酸の3-(1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチル-トリデシル)-1-ベンゾピラン-6-イルビスエステル
ペンタン二酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチル-トリデシル)-1-ベンゾピラン-6-イルビスエステル
TLC (ヘプタン/酢酸エチル 7/3): Rf = 0.6
Claims (17)
- 下記式(I)の化合物、それらの鏡像異性体およびジアステレオ異性体、並びに酸または生理学的に許容可能な塩基への付加により生じる任意の塩:
R1はR'1または-A-R'1基であり、R'1は-COOH、-COOR3、-CONH2、-CONHR3、-CONR3R4、-CHO、-CH2OH、-CH2OR5から選択され、Aは直鎖状もしくは分岐状のC1-C16アルキレン基、直鎖状もしくは分岐状のC2-C16アルケニレン基、または直鎖状もしくは分岐状のC2-C16アルキニレン基であり、
R2は:
・場合によって置換されたアリール基もしくは場合によって置換されたヘテロアリール基、または
・オシド残基、または
・場合によって分岐しおよび/または好ましくは鎖の末端が、特にヒドロキシ、アセトキシ、または保護されたもしくは保護されていないアミノ残基によって置換された脂肪酸残基、
・-OC-(CH2)nCO-(α、β、γ、またはδ)トコフェリル基(但し、2≦n≦10)、
・-R'2-O-R6基
(上記式中、R'2は場合によって置換されたアリーレン基または場合によって置換されたヘテロアリーレン基であり、R6は水素原子、直鎖状もしくは分岐状の場合によって置換されたC1-C16アルキル基、直鎖状もしくは分岐状の場合によって置換されたC2-C16アルケニル基、または直鎖状もしくは分岐状の場合によって置換されたC2-C16アルキニル基、直鎖状もしくは分岐状の場合によって置換されたトコフェリル基もしくは類似体、アミノ酸残基、またはオシド残基である)を表し、
R3およびR4は、独立して、直鎖状もしくは分岐状の場合によって置換されたC1-C16アルキル基、直鎖状もしくは分岐状のC2-C16アルケニル、または直鎖状もしくは分岐状の場合によって置換されたC2-C16アルキニルであり、
R5は、直鎖状もしくは分岐状の場合によって置換されたC1-C16アルキル基、直鎖状もしくは分岐状の場合によって置換されたC2-C16アルケニル基、直鎖状もしくは分岐状の場合によって置換されたC2-C16アルキニル基、または直鎖状もしくは分岐状の場合によって置換されたC2-C16アシル基である)。 - R1が、-COOH、-COOR3、-CHO、-CH2OH、-CH2OR5(上記式中、R3およびR5は請求項1において定義した通りである)から選択される基である、請求項1に記載の式(I)の化合物。
- Aがメチレン基である、請求項1に記載の式(I)の化合物。
- R2が基-R'2-O-R6(上記式中、R'2は場合によって置換されたアリーレン基であり、R6は直鎖状もしくは分岐状の(C1-C6)アルキル基またはオシド残基である)である、請求項1−3のいずれか一項に記載の式(I)の化合物。
- R'2がフェニレン基であり、R6がグルコース、ガラクトース、フルクトース、マンノース、フコース、ラムノースから選択される糖残基である、請求項4に記載の式(I)の化合物。
- 下記から選択される、請求項1に記載の式(I)の化合物:
(2E,4E,6E,8E)-3,7-ジメチル-9-{2,6,6-トリメチル-3-[4-((2S,3R,4S,5S,6R)-3,4,5-トリヒドロキシ-6-ヒドロキシメチル-テトラヒドロ-ピラン-2-イルオキシ)-フェノキシ]-シクロへキス-1-エニル}-ノナ-2,4,6,8-テトラエン酸、
(2E,4E,6E,8E)-9-[3-(4-メトキシ-フェノキシ)-2,6,6-トリメチル-シクロへキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル、
(2E,4E,6E,8E)-9-[3-(4-メトキシ-フェノキシ)-2,6,6-トリメチル-シクロへキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール、
(2E,4E,6E,8E)-9-[3-(4-ヒドロキシ-フェノキシ)-2,6,6-トリメチル-シクロへキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル、
(2E,4E,6E,8E)-9-[3-(4-ヒドロキシ-フェノキシ)-2,6,6-トリメチル-シクロへキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール、
(2E,4E,6E,8E)-3,7-ジメチル-9-{2,6,6-トリメチル-3-ジメチル-[4-((2S,3R,4S,5S,6R)-3,4,5-トリヒドロキシ-6-ヒドロキシメチル-テトラヒドロ-ピラン-2-イルオキシ)-フェノキシ]-シクロへキス-1-エニル}-ノナ-2,4,6,8-テトラエナール、
9-[(3-トランスデセノエート)-2,6,6-トリメチル-シクロへキス-1-エニル}-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール、
9-[(3-リノレエート)-2,6,6-トリメチル-シクロへキス-1-エニル}-3,7-ジメチルノナ-2,4,6,8-テトラエナール、
9-[(3-リノレネート)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール、
(9Z,12Z,15Z)-オクタデカ-9,12,15-トリエン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル、
9-[(3-リポエート)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ-2,4,6,8-テトラエナール、
9-[{3-(8-ヒドロキシ-5-メチル-2-オクテノエート)}-2,6,6-トリメチル-シクロヘキス-1-エニル]- 3,7-ジメチル-ノナ-2,4,6,8-テトラエナール、
(E)-14-ヒドロキシ-テトラデク-2-エン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル、
(E)-10-ヒドロキシ-デク-2-エン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル、
(E)-10-アセトキシ-デク-2-エン酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルエステル、
9-[(3-テトラアセチルグルコース)-2,6,6-トリメチル-シクロヘキス-1-エニル]-3,7-ジメチル-ノナ- 2,4,6,8-テトラエナール、
ヘプタン二酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチル-トリデシル)-1-ベンゾピラン-6-イルビスエステル、
ノナン二酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチルトリデシル)-1-ベンゾピラン-6-イルのビスエステル、
コハク酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチルトリデシル)-1-ベンゾピラン-6-イルのビスエステル、
ペンタン二酸の3-((1E,3E,5E,7E)-3,7-ジメチル-9-オキソ-ノナ-1,3,5,7-テトラエニル)-2,4,4-トリメチル-シクロヘキス-2-エニルおよび(R)-2,8-ジメチル-2-((4R,8R)-4,8,12-トリメチル-トリデシル)-1-ベンゾピラン-6-イルのビスエステル。 - 請求項1−6のいずれか一項に記載の式(I)の化合物の製造方法であって、式(II)の化合物:
の3位においてアリル酸化反応を行い、式(III)の化合物:
を得て、
次に、その3位のカルボニル基を還元して対応する式(IV)のアルコール:
化合物(IV)をアルカリ性、酸性、または中性媒質中において、場合によりカップリング試薬の存在下にて、式R2-X (上記式中、Xはヒドロキシ基またはハロゲン原子であるが、前記ヒドロキシ基は必要ならば出発基の形態において当然活性化させることができる)の試薬を用いてアルキル化反応またはカップリング反応を行って、式(I)の化合物の具体例である式(Ia)の化合物:
を生成させ、
これを、基R10が請求項1に記載の基-COOR3である場合には、加水分解または還元反応を行って、式(I)の化合物の具体例である式(Ib)の化合物:
を生成させることができ、
上記化合物に含まれる様々な基は、当然、用いられる試薬の不適合性に依存し、保護後、任意の時間に脱保護した基の合成に適切であることを特徴とする、方法。 - 請求項8に記載の式(IIIa)の(2E,4E,6E,8E)-9-(3-オキソ-2,6,6-トリメチル-シクロヘキス-1-エニル)-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル。
- 請求項10に記載の式(IVa)の(2E,4E,6E,8E)-9-(3-ヒドロキシ-2,6,6-トリメチル-シクロヘキス-1-エニル)-3,7-ジメチル-ノナ-2,4,6,8-テトラエン酸の第三ブチルエステル。
- 生理学的に許容可能な媒質中に請求項1−6のいずれか一項に記載の少なくとも一種類の式(I)の化合物を含むことを特徴とする、化粧用または皮膚用組成物。
- 前記式(I)の化合物の量が、組成物の総重量の0.01重量%-5重量%の範囲であることを特徴とする、請求項12に記載の組成物。
- 請求項1−6のいずれか一項に記載の少なくとも一種類の式(I)の化合物を含む化粧用組成物を、皮膚および/または体毛および/または頭髪に塗布することを含んでなる、ヒトの皮膚および/または体毛および/または頭髪を白色化および/または美白化する方法。
- 皮膚および/または体毛および/または頭髪の脱色素のための使用を目的とする皮膚用組成物を製造するための、請求項1−6のいずれか一項に記載の少なくとも一種類の式(I)の化合物の使用。
- 医薬品として使用するための、請求項1−6のいずれか一項に記載の式(I)の化合物。
- 皮膚の脱色素のための使用を目的とする組成物を製造するための、請求項1−6のいずれか一項に記載の少なくとも1種類の式(I)の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0512661 | 2005-12-14 | ||
FR0512661A FR2894577B1 (fr) | 2005-12-14 | 2005-12-14 | Nouveaux composes polyinsatures, leur procede de preparation et les compositions les contenant. |
PCT/EP2006/069731 WO2007068745A1 (fr) | 2005-12-14 | 2006-12-14 | Nouveaux composés polyinsaturés, leur procédé de préparation et les compositions les contenant |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009519298A true JP2009519298A (ja) | 2009-05-14 |
JP5306819B2 JP5306819B2 (ja) | 2013-10-02 |
Family
ID=36649328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008545006A Expired - Fee Related JP5306819B2 (ja) | 2005-12-14 | 2006-12-14 | 新規なポリ不飽和化合物、これらの化合物の製造方法、およびこれらの化合物を含む組成物 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8420610B2 (ja) |
EP (1) | EP1968993B1 (ja) |
JP (1) | JP5306819B2 (ja) |
KR (1) | KR20080077003A (ja) |
CN (1) | CN101356182A (ja) |
AT (1) | ATE540964T1 (ja) |
AU (1) | AU2006325223C1 (ja) |
BR (1) | BRPI0619959A2 (ja) |
CA (1) | CA2633225C (ja) |
FR (1) | FR2894577B1 (ja) |
IL (1) | IL192065A (ja) |
MA (1) | MA30160B1 (ja) |
MX (1) | MX2008007792A (ja) |
NZ (1) | NZ569321A (ja) |
RU (1) | RU2466988C2 (ja) |
TN (1) | TNSN08261A1 (ja) |
UA (1) | UA97104C2 (ja) |
WO (1) | WO2007068745A1 (ja) |
ZA (1) | ZA200805740B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009519297A (ja) * | 2005-12-14 | 2009-05-14 | ピエール、ファブレ、デルモ‐コスメティーク | ポリ不飽和化合物の美白化剤としての使用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5447954B2 (ja) * | 2007-09-19 | 2014-03-19 | 公益財団法人名古屋産業科学研究所 | 神経栄養因子様作用剤 |
CN101591280B (zh) * | 2008-05-30 | 2012-08-22 | 安徽医科大学 | 具有肿瘤诱导分化作用的类维甲酸衍生物及其药物组合物与用途 |
FR2945442B1 (fr) | 2009-05-14 | 2012-08-03 | Fabre Pierre Dermo Cosmetique | Utilisation de delta-tocopheryl-glucide en tant qu'agent depigmentant. |
EP3689342A1 (en) * | 2011-04-26 | 2020-08-05 | Retrotope, Inc. | Oxidative retinal diseases |
CA2981080A1 (en) * | 2015-04-15 | 2016-10-20 | Valent Biosciences Llc | (s)-2'-vinyl-abscisic acid derivatives |
CN114029072B (zh) * | 2021-12-01 | 2023-07-11 | 万华化学集团股份有限公司 | 一种固体超强酸催化剂及用其制备对甲氧基肉桂酸异辛酯的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3068257A (en) * | 1962-12-11 | Cxchs | ||
US3311656A (en) * | 1964-05-12 | 1967-03-28 | Hoffmann La Roche | Intermediates for the preparation of a carotenoid |
JP2004509073A (ja) * | 2000-07-11 | 2004-03-25 | ユニバーシティ・オブ・メリーランド, ボルティモア | 新規なc−4置換レチノイド |
JP2009519297A (ja) * | 2005-12-14 | 2009-05-14 | ピエール、ファブレ、デルモ‐コスメティーク | ポリ不飽和化合物の美白化剤としての使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786391A (en) * | 1995-01-11 | 1998-07-28 | Cornell Research Foundation, Inc. | Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position |
FR2791679B1 (fr) | 1999-03-31 | 2003-04-11 | Fabre Pierre Dermo Cosmetique | Bioprecurseurs aptes a liberer un derive retinoique par mise a profit de l'activite enzymatique de la surface cutanee et compositions pharmaceutiques et/ou cosmetiques |
ATE357431T1 (de) * | 2001-10-31 | 2007-04-15 | Dsm Ip Assets Bv | Herstellung von retinoiden |
-
2005
- 2005-12-14 FR FR0512661A patent/FR2894577B1/fr not_active Expired - Fee Related
-
2006
- 2006-12-14 EP EP06841375A patent/EP1968993B1/fr active Active
- 2006-12-14 KR KR1020087016703A patent/KR20080077003A/ko not_active Application Discontinuation
- 2006-12-14 MX MX2008007792A patent/MX2008007792A/es active IP Right Grant
- 2006-12-14 CN CNA2006800508101A patent/CN101356182A/zh active Pending
- 2006-12-14 NZ NZ569321A patent/NZ569321A/en not_active IP Right Cessation
- 2006-12-14 AU AU2006325223A patent/AU2006325223C1/en not_active Ceased
- 2006-12-14 UA UAA200809182A patent/UA97104C2/ru unknown
- 2006-12-14 JP JP2008545006A patent/JP5306819B2/ja not_active Expired - Fee Related
- 2006-12-14 AT AT06841375T patent/ATE540964T1/de active
- 2006-12-14 CA CA2633225A patent/CA2633225C/fr not_active Expired - Fee Related
- 2006-12-14 WO PCT/EP2006/069731 patent/WO2007068745A1/fr active Application Filing
- 2006-12-14 BR BRPI0619959-3A patent/BRPI0619959A2/pt not_active IP Right Cessation
- 2006-12-14 RU RU2008128318/04A patent/RU2466988C2/ru not_active IP Right Cessation
- 2006-12-14 US US12/086,625 patent/US8420610B2/en not_active Expired - Fee Related
-
2008
- 2008-06-11 IL IL192065A patent/IL192065A/en not_active IP Right Cessation
- 2008-06-13 TN TNP2008000261A patent/TNSN08261A1/fr unknown
- 2008-07-01 ZA ZA200805740A patent/ZA200805740B/xx unknown
- 2008-07-11 MA MA31113A patent/MA30160B1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3068257A (en) * | 1962-12-11 | Cxchs | ||
US3311656A (en) * | 1964-05-12 | 1967-03-28 | Hoffmann La Roche | Intermediates for the preparation of a carotenoid |
JP2004509073A (ja) * | 2000-07-11 | 2004-03-25 | ユニバーシティ・オブ・メリーランド, ボルティモア | 新規なc−4置換レチノイド |
JP2009519297A (ja) * | 2005-12-14 | 2009-05-14 | ピエール、ファブレ、デルモ‐コスメティーク | ポリ不飽和化合物の美白化剤としての使用 |
Non-Patent Citations (7)
Title |
---|
JPN6012034375; Bioorganic & Medicinal Chemistry Letters Vol.2, No.9, p.1133-1136 (1992). * |
JPN6012034377; Journal of Organic Chemistry Vol.47, No.9, p.1698-1701 (1982). * |
JPN6012034380; Helvetica Chimica Acta Vol.43, p.94-101 (1960). * |
JPN6012034382; Bioorganicheskaya Khimiya Vol.7, No.11, p.1731-1733 (1981). * |
JPN6012034384; Photochemistry and Photobiology Vol.33, No.4, p.483-488 (1981). * |
JPN6012034386; Tetrahedron Letters Vol.35, No.6, p.905-908 (1994). * |
JPN6012034388; Journal of Biological Chemistry Vol.275, No.10, p.6908-6914 (2000). * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009519297A (ja) * | 2005-12-14 | 2009-05-14 | ピエール、ファブレ、デルモ‐コスメティーク | ポリ不飽和化合物の美白化剤としての使用 |
US8481011B2 (en) | 2005-12-14 | 2013-07-09 | Pierre Fabre Dermo-Cosmetique | Use of polyunsaturated compounds as whitening agents |
Also Published As
Publication number | Publication date |
---|---|
FR2894577B1 (fr) | 2008-02-22 |
RU2008128318A (ru) | 2010-01-20 |
US20100168045A1 (en) | 2010-07-01 |
ATE540964T1 (de) | 2012-01-15 |
AU2006325223C1 (en) | 2013-03-14 |
WO2007068745A1 (fr) | 2007-06-21 |
CA2633225A1 (fr) | 2007-06-21 |
FR2894577A1 (fr) | 2007-06-15 |
CA2633225C (fr) | 2014-11-18 |
MX2008007792A (es) | 2008-09-15 |
NZ569321A (en) | 2010-04-30 |
EP1968993B1 (fr) | 2012-01-11 |
AU2006325223B2 (en) | 2012-07-19 |
KR20080077003A (ko) | 2008-08-20 |
US8420610B2 (en) | 2013-04-16 |
EP1968993A1 (fr) | 2008-09-17 |
TNSN08261A1 (fr) | 2009-10-30 |
MA30160B1 (fr) | 2009-01-02 |
BRPI0619959A2 (pt) | 2011-10-25 |
UA97104C2 (ru) | 2012-01-10 |
RU2466988C2 (ru) | 2012-11-20 |
ZA200805740B (en) | 2009-08-26 |
IL192065A0 (en) | 2008-12-29 |
IL192065A (en) | 2013-09-30 |
JP5306819B2 (ja) | 2013-10-02 |
CN101356182A (zh) | 2009-01-28 |
AU2006325223A1 (en) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5306819B2 (ja) | 新規なポリ不飽和化合物、これらの化合物の製造方法、およびこれらの化合物を含む組成物 | |
KR101961884B1 (ko) | 아릴, 헤테로아릴, 오-아릴 및 오-헤테로 아릴 족 카르바슈가 | |
EP2837621B1 (en) | Processes and intermediates for the preparations of isomer free prostaglandins | |
CA2492940A1 (fr) | Nouveaux composes gem difluores, leurs procedes de preparation et leurs applications | |
HU205894B (en) | Process for producing optically active ceramide type compounds | |
JPH04108797A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
KR980009260A (ko) | 오시란카르복실산 유도체 및 그의 제조방법 | |
US20030171621A1 (en) | Process for the synthesis of sphingosine | |
KR100778191B1 (ko) | 소가올 화합물 및 이를 포함하는 티로시나아제 활성 억제제 | |
JP2002193990A (ja) | ハイドロカルコン配糖体および該配糖体を有効成分として配合した化粧料 | |
US6818657B1 (en) | Bioprecursors of a retinoic derivative and pharmaceutical and/or cosmetic compositions | |
JP7141025B1 (ja) | 化合物、組成物、方法、及び製造方法 | |
EP1466590B1 (fr) | Utilisation cosmétique de nouveaux agents desquamants | |
KR20190042625A (ko) | 탈색소제 또는 미백제로서 디플루오르화된 화합물 | |
EA010020B1 (ru) | Соединение карбоновой кислоты и лекарственное средство, его включающее | |
JPH0631297B2 (ja) | 新規なアントラサイクリン類およびその製造方法 | |
JPH10175907A (ja) | 2,3−ジ置換シクロペンタノンの医薬用途、該化合物の製造法及び新規化合物 | |
EP0372571A2 (en) | Novel sphingenine and derivatives thereof | |
FR2826367A1 (fr) | Nouveaux derives de [4-(4-cyanobenzoyl)phenyl] glycopyranoside, utilisation en tant que medicamment, procede d'obtention et compositions pharmaceutiques les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091130 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121003 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121011 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130531 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130626 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |